The hierarchical Bayesian meta-analysis (2004) demonstrated a significant reduction in the rate of angiographic restenosis and major adverse cardiac events observed with the<unk><unk> <unk> (sirolimus or paclitaxel) in comparison to the bare-metal<unk> ; however, there was no evidence that they affect mortality or myocardial infarction rates. A recent update on<unk><unk><unk>  (2008), reported similar success rates and side effects associated with both the Cypher (sirolimus<unk>  and the TAXUS (paclitaxel<unk><unk> ; hence, suggested a similar benefit may be replicated in routine clinical practice. The prevention of neointimal hyperplasia is no longer the ultimate goal and has been replaced by the development of more biocompatible and bioabsorbable<unk>  that facilitate adequate endothelialization.
Chronic stable angina revascularization drug eluting stents
Chronic stable angina revascularization percutaneous coronary intervention
Chronic stable angina treatment calcium channel blockers
Chronic stable angina treatment dipyridamole
Chronic stable angina treatment anti-lipid agents
Chronic stable angina revascularization coronary artery bypass grafting
Chronic stable angina treatment aspirin
Chronic stable angina treatment angiotensin converting enzyme inhibitors 